Market Overview - On October 9, the medical services sector rose by 0.91%, with Jiuzhou Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Top Gainers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 20.61, up 5.96% with a trading volume of 418,800 shares and a transaction value of 844 million [1] - Meinian Health (002044) closed at 5.20, up 4.63% with a trading volume of 1,667,200 shares and a transaction value of 871 million [1] - Heyuan Biotechnology (688238) closed at 8.20, up 4.19% with a trading volume of 344,500 shares and a transaction value of 285 million [1] - Sanbo Brain Science (301293) closed at 60.80, up 4.02% with a trading volume of 110,100 shares and a transaction value of 660 million [1] - Haoyuan Pharmaceutical (688131) closed at 85.48, up 3.49% with a trading volume of 59,800 shares and a transaction value of 508 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 14.21, down 8.73% with a trading volume of 68,800 shares and a transaction value of 96.92 million [2] - ST Biological (000504) closed at 9.07, down 4.02% with a trading volume of 46,100 shares and a transaction value of 42.42 million [2] - Baicheng Pharmaceutical (301096) closed at 57.99, down 3.35% with a trading volume of 32,600 shares and a transaction value of 191 million [2] Fund Flow Analysis - The medical services sector experienced a net outflow of 308 million from institutional investors, while retail investors saw a net inflow of 348 million [2] - The net outflow from retail investors amounted to 40.85 million [2] Individual Stock Fund Flow - Aier Eye Hospital (300015) had a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 137 million [3] - Sanbo Brain Science (301293) saw a net inflow of 63.69 million from institutional investors, with retail investors facing a net outflow of 45.84 million [3] - Jiuzhou Pharmaceutical (603456) had a net inflow of 53.54 million from institutional investors, while retail investors faced a net outflow of 63.40 million [3]

证券代码：603456 证券简称：九洲药业 公告编号：2025-056 浙江九洲药业股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 二、说明会召开的时间、地点及方式 1、会议召开时间：2025 年 10 月 16 日（星期四）11:00-12:00 2 、 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开时间：2025 年 10 月 16 日（星期四）11:00-12:00 会议召开方式：上证路演中心网络互动 3、会议召开方式：上证路演中心网络互动 三、公司参加人员 董事兼总裁梅义将先生；董事、执行副总裁兼财务负责人沙裕杰先生；董事、 执行副总裁兼董事会秘书林辉潞先生；独立董事杨立荣 ...

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Jiuzhou Pharmaceutical, including stock price movements and trading volumes [1][2] - As of September 29, Jiuzhou Pharmaceutical's stock price increased by 2.06%, reaching 19.32 CNY per share, with a total market capitalization of 17.184 billion CNY [1] - The company has seen a year-to-date stock price increase of 46.52%, with a 1.68% rise over the last five trading days and a 28.87% increase over the last 60 days [1] Group 2 - Jiuzhou Pharmaceutical's main business revenue composition includes 79.81% from new drug custom development and production services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] - For the first half of 2025, Jiuzhou Pharmaceutical reported a revenue of 2.871 billion CNY, reflecting a year-on-year growth of 3.86%, and a net profit attributable to shareholders of 526 million CNY, up 10.70% [2][3] - The company has distributed a total of 2.183 billion CNY in dividends since its A-share listing, with 1.245 billion CNY distributed in the last three years [3]

Market Overview - On September 25, the medical services sector rose by 0.78%, with Bid Pharma leading the gains [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Top Gainers in Medical Services - Bid Pharma (688073) closed at 79.56, up 6.61% with a trading volume of 18,000 hands and a transaction value of 141 million [1] - Jiuzhou Pharmaceutical (603456) closed at 19.46, up 5.65% with a trading volume of 749,100 hands and a transaction value of 1.484 billion [1] - Yaokang Bio (688046) closed at 19.10, up 3.24% with a trading volume of 39,200 hands and a transaction value of 74.36 million [1] Top Losers in Medical Services - Baicheng Pharma (301096) closed at 60.30, down 6.37% with a trading volume of 94,600 hands and a transaction value of 583 million [2] - Haochen Medical (002622) closed at 3.83, down 3.04% with a trading volume of 465,400 hands and a transaction value of 181 million [2] - Chengda Pharmaceutical (301201) closed at 29.79, down 2.84% with a trading volume of 33,300 hands and a transaction value of 100 million [2] Capital Flow Analysis - The medical services sector saw a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 28.43 million [2] - Jiuzhou Pharmaceutical had a net inflow of 191 million from institutional investors, but a net outflow of 93.86 million from retail investors [3] - Bid Pharma experienced a net inflow of 19.49 million from institutional investors, with a net outflow of 8.87 million from retail investors [3]

Group 1 - The medical sector in A-shares remains active, with the largest medical ETF (512170) rising over 1% and recovering its 5-day moving average, with a trading volume exceeding 480 million yuan [1] - Major stocks in the medical device and CXO sectors saw significant gains, with Mindray Medical rising over 4% and Jiuzhou Pharmaceutical hitting a daily limit before closing nearly 6% higher [1] - Conversely, companies like Meihua Medical and Yingke Medical experienced notable declines [1] Group 2 - The release of the industry standard for medical devices using brain-computer interface technology on September 18 is expected to promote the standardized application of this technology in the medical field [1][3] - Global brain initiatives are driving the development of brain-computer interface technology, with China's first industry standard establishing a unified technical language for the sector [3] - The Shanghai government has announced an action plan to promote the development of high-end medical devices, aiming to add over 500 Class III medical device registration certificates by 2027 and cultivate two hundred billion-level leading enterprises [3] Group 3 - The medical ETF (512170) passively tracks the CSI Medical Index, with its top ten weighted stocks including WuXi AppTec, Mindray Medical, and others [3] - The medical device sector is anticipated to reach a turning point in the second half of the year due to improvements in anti-corruption measures, centralized procurement, and equipment purchasing [3]

Group 1 - The CRO concept stocks experienced significant fluctuations, with JiuZhou Pharmaceutical hitting the daily limit up [1] - ProLogis Pharmaceutical rose over 5%, indicating strong market interest [1] - Other companies such as Zhaoyan New Drug, Kangpeng Technology, Aopu Mai, and Haoyuan Pharmaceutical also saw increases in their stock prices [1]

Group 1 - The CRO index experienced an intraday increase of 2.01%, indicating strong market performance in the sector [1] - Jiuzhou Pharmaceutical reached its daily limit up, showcasing significant investor interest [1] - Zhaoyan New Drug and Aopu Mai saw respective increases of 3.49% and 3.40%, reflecting positive momentum among key players [1] - WuXi AppTec and Kelai Ying both recorded gains exceeding 2.5%, further highlighting the active performance of the CRO sector [1]

Core Viewpoint - Jiuzhou Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 39.77% but a recent decline of 8.90% over the past five trading days [1] Company Overview - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, is located in Taizhou, Zhejiang Province. The company specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1] - The company's revenue composition includes 79.81% from new drug custom development and production services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Financial Performance - For the first half of 2025, Jiuzhou Pharmaceutical achieved operating revenue of 2.871 billion yuan, representing a year-on-year growth of 3.86%. The net profit attributable to shareholders was 526 million yuan, up 10.70% year-on-year [2] - The company has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed over the past three years [3] Shareholder Information - As of June 30, 2025, Jiuzhou Pharmaceutical had 53,700 shareholders, a decrease of 0.57% from the previous period. The average number of circulating shares per shareholder was 16,571, down 0.08% [2] - The top ten circulating shareholders include notable funds such as Huabao Zhongzheng Medical ETF and Zhongou Medical Health Mixed A, with varying changes in their holdings [3]

Group 1 - The core viewpoint of the news is that Jiuzhou Pharmaceutical's stock has experienced a significant decline, with a drop of 5.05% on September 23, leading to a total market value of 16.046 billion yuan and a cumulative decline of 6.22% over four consecutive days [1] - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates, with its main business revenue composition being 79.81% from new drug custom development and production services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1] Group 2 - From the perspective of Jiuzhou Pharmaceutical's top circulating shareholders, Huabao Fund's Huabao CSI Medical ETF (512170) increased its holdings by 467,700 shares in the second quarter, now holding 17.7854 million shares, which accounts for 2% of the circulating shares, resulting in a floating loss of approximately 17.074 million yuan today and a total floating loss of 22.4096 million yuan during the four-day decline [2] - The Huabao CSI Medical ETF (512170), established on May 20, 2019, has a current scale of 26.147 billion yuan, with a year-to-date return of 18.43% and a one-year return of 42.82%, ranking 2736 out of 4220 and 2434 out of 3814 in its category, respectively [2]

Core Viewpoint - Jiuzhou Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 40.91% but a recent decline of 8.29% over the past five trading days [1] Financial Performance - For the first half of 2025, Jiuzhou Pharmaceutical reported revenue of 2.871 billion yuan, a year-on-year increase of 3.86%, and a net profit attributable to shareholders of 526 million yuan, up 10.70% year-on-year [2] - The company has distributed a total of 2.183 billion yuan in dividends since its A-share listing, with 1.245 billion yuan distributed in the last three years [3] Stock Market Activity - As of September 23, Jiuzhou Pharmaceutical's stock price was 18.58 yuan per share, with a market capitalization of 16.526 billion yuan [1] - The stock has seen a net outflow of 9.245 million yuan in principal funds, with significant buying and selling activity from large orders [1] Shareholder Information - As of June 30, 2025, Jiuzhou Pharmaceutical had 53,700 shareholders, a decrease of 0.57% from the previous period, with an average of 16,571 circulating shares per shareholder [2] - Major shareholders include Huabao Zhongzheng Medical ETF and other funds, with varying changes in their holdings [3]